To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||To Compare the Efficacy and Safety of TW vs Valsartan in the MN|
- To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- To investigate the safety and tolerability of TW vs ARB in treatment of MN [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||July 2007|
|Study Completion Date:||September 2009|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Other Name: TW,Tripterygium wilfordii Hook.f
Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.
Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00518219
|Research Institute of Nephrology|
|Nanjing, Jiangsu, China, 210002|
|Principal Investigator:||Zhihong Liu, Master||Jinling Hospital, China|